Global Renal Anemia Therapeutics Market 2018-2022
出 版 商：Technavio
出版日期：2018/07/11
頁 數：101頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
About Renal Anemia Therapeutics
Anemia is a medical condition characterized by the body producing fewer red blood cells (RBCs)than normal, which results in a decline in oxygen delivery to vital tissues and organs. Renal anemia refers to anemia that occurs due to renal dysfunction or chronic kidney disease (CKD).
Technavio’s analysts forecast the global renal anemia therapeutics market to grow at a CAGR of 8.33% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global renal anemia therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Renal Anemia Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ AMAG Pharmaceuticals
‧ AstraZeneca
‧ Daiichi Sankyo
‧ GlaxoSmithKline
‧ PHARMACOSMOS
Market driver
‧ Presence of large pool of CKD patients
‧ For a full, detailed list, view our report
Market challenge
‧ Side-effects of oral administration
‧ For a full, detailed list, view our report
Market trend
‧ Growing focus of vendors on emerging economies
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Anemia is a medical condition characterized by the body producing fewer red blood cells (RBCs)than normal, which results in a decline in oxygen delivery to vital tissues and organs. Renal anemia refers to anemia that occurs due to renal dysfunction or chronic kidney disease (CKD).
Technavio’s analysts forecast the global renal anemia therapeutics market to grow at a CAGR of 8.33% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global renal anemia therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Renal Anemia Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ AMAG Pharmaceuticals
‧ AstraZeneca
‧ Daiichi Sankyo
‧ GlaxoSmithKline
‧ PHARMACOSMOS
Market driver
‧ Presence of large pool of CKD patients
‧ For a full, detailed list, view our report
Market challenge
‧ Side-effects of oral administration
‧ For a full, detailed list, view our report
Market trend
‧ Growing focus of vendors on emerging economies
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY APPLICATION
‧ Segmentation by application
‧ Comparison by application
‧ IV – Market size and forecast 2017-2022
‧ Oral – Market size and forecast 2017-2022
‧ Market opportunity by application
PART 08: MARKET SEGMENTATION BY PRODUCT
‧ Segmentation by product
‧ Epoetin alfa
‧ Epoetin beta
‧ Others
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas – Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Key leading countries
‧ Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 13: MARKET TRENDS
‧ Growing focus of vendors on emerging economies
‧ Increasing instances of strategic collaborations among vendors
‧ Rising number of drugs in pipeline
PART 14: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 15: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ AMAG Pharmaceuticals
‧ AstraZeneca
‧ Daiichi Sankyo
‧ GlaxoSmithKline
‧ PHARMACOSMOS
PART 16: APPENDIX
‧ List of abbreviations
?
Exhibit 01: Parent market
Exhibit 02: Global CKD therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Application – Market share 2017-2022 (%)
Exhibit 19: Comparison by application
Exhibit 20: IV – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: IV – Year-over-year growth 2018-2022 (%)
Exhibit 22: Oral – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Oral – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Global – Market share by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 32: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Vendor landscape
Exhibit 37: Landscape disruption
Exhibit 38: Vendors covered
Exhibit 39: Vendor classification
Exhibit 40: Market positioning of vendors
Exhibit 41: AMAG Pharmaceuticals: Overview
Exhibit 42: AMAG Pharmaceuticals – Business segments
Exhibit 43: AMAG Pharmaceuticals – Organizational developments
Exhibit 44: AMAG Pharmaceuticals – Key offerings
Exhibit 45: AstraZeneca: Overview
Exhibit 46: AstraZeneca – Business segments
Exhibit 47: AstraZeneca – Organizational developments
Exhibit 48: AstraZeneca – Geographic focus
Exhibit 49: AstraZeneca – Key offerings
Exhibit 50: Daiichi Sankyo: Overview
Exhibit 51: Daiichi Sankyo – Business segments
Exhibit 52: Daiichi Sankyo – Organizational developments
Exhibit 53: Daiichi Sankyo – Geographic focus
Exhibit 54: Daiichi Sankyo: Segment focus
Exhibit 55: Daiichi Sankyo – Key offerings
Exhibit 56: GlaxoSmithKline: overview
Exhibit 57: GlaxoSmithKline – Business segments
Exhibit 58: GlaxoSmithKline – Organizational developments
Exhibit 59: GlaxoSmithKline – Geographic focus
Exhibit 60: GlaxoSmithKline – Segment focus
Exhibit 61: GlaxoSmithKline – Key offerings
Exhibit 62: PHARMACOSMOS: Overview
Exhibit 63: PHARMACOSMOS – Business segment
Exhibit 64: PHARMACOSMOS – Organizational developments
Exhibit 65: PHARMACOSMOS – Key offerings
?
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY APPLICATION
‧ Segmentation by application
‧ Comparison by application
‧ IV – Market size and forecast 2017-2022
‧ Oral – Market size and forecast 2017-2022
‧ Market opportunity by application
PART 08: MARKET SEGMENTATION BY PRODUCT
‧ Segmentation by product
‧ Epoetin alfa
‧ Epoetin beta
‧ Others
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas – Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Key leading countries
‧ Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 13: MARKET TRENDS
‧ Growing focus of vendors on emerging economies
‧ Increasing instances of strategic collaborations among vendors
‧ Rising number of drugs in pipeline
PART 14: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 15: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ AMAG Pharmaceuticals
‧ AstraZeneca
‧ Daiichi Sankyo
‧ GlaxoSmithKline
‧ PHARMACOSMOS
PART 16: APPENDIX
‧ List of abbreviations
?
Exhibit 01: Parent market
Exhibit 02: Global CKD therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Application – Market share 2017-2022 (%)
Exhibit 19: Comparison by application
Exhibit 20: IV – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: IV – Year-over-year growth 2018-2022 (%)
Exhibit 22: Oral – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Oral – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Global – Market share by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 32: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 33: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Vendor landscape
Exhibit 37: Landscape disruption
Exhibit 38: Vendors covered
Exhibit 39: Vendor classification
Exhibit 40: Market positioning of vendors
Exhibit 41: AMAG Pharmaceuticals: Overview
Exhibit 42: AMAG Pharmaceuticals – Business segments
Exhibit 43: AMAG Pharmaceuticals – Organizational developments
Exhibit 44: AMAG Pharmaceuticals – Key offerings
Exhibit 45: AstraZeneca: Overview
Exhibit 46: AstraZeneca – Business segments
Exhibit 47: AstraZeneca – Organizational developments
Exhibit 48: AstraZeneca – Geographic focus
Exhibit 49: AstraZeneca – Key offerings
Exhibit 50: Daiichi Sankyo: Overview
Exhibit 51: Daiichi Sankyo – Business segments
Exhibit 52: Daiichi Sankyo – Organizational developments
Exhibit 53: Daiichi Sankyo – Geographic focus
Exhibit 54: Daiichi Sankyo: Segment focus
Exhibit 55: Daiichi Sankyo – Key offerings
Exhibit 56: GlaxoSmithKline: overview
Exhibit 57: GlaxoSmithKline – Business segments
Exhibit 58: GlaxoSmithKline – Organizational developments
Exhibit 59: GlaxoSmithKline – Geographic focus
Exhibit 60: GlaxoSmithKline – Segment focus
Exhibit 61: GlaxoSmithKline – Key offerings
Exhibit 62: PHARMACOSMOS: Overview
Exhibit 63: PHARMACOSMOS – Business segment
Exhibit 64: PHARMACOSMOS – Organizational developments
Exhibit 65: PHARMACOSMOS – Key offerings
?
